alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
**EXHIBIT 4.5.6**

**Amendment No. 6****To License No. 14710 (series A 014123)****dated April 7, 2000**

Legal address on the title page of the License shall read as follows:

“127083, Moscow, Ul. Vosmogo Marta, 10, bldg. 14.”

 

| **First Deputy Minister****of the Russian Federation for****Communications and Information** |   | [Signature] |   | Yu.A. Pavlenko |   |
|----------------------------------------------------------------------------------------------|--------|-------------|--------|----------------|--------|
|                                                                                         |   |        |   |           |   |
|                                                                                         |   |        |   | June 13, 2002  |   |

 

| **Head of the Department****of the Organization****of Licensing Activity** |   | [Signature] |   | B.V. Vorobiev |   |
|----------------------------------------------------------------------------|--------|-------------|--------|--------------------|--------|
|                                                                       |   | [Seal]      |   |               |   |
|                                                                       |   |        |   |               |   |
**Exhibit 32.1**

** **

**CERTIFICATION OF CHIEF EXECUTIVE OFFICERAND CHIEF FINANCIAL OFFICER**

**PURSUANT TO 18 U.S.C. SECTION 1350,**

**AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACTOF 2002**

 

 

The undersigned, Paul Knudson, the Chief Executive Officerand Chief Financial Officer of Therapy Cells Inc. (formerly known as Diamond Information Institute Inc.), hereby certify pursuantto 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to their knowledge, theForm 10-Q of Therapy Cells, Inc., fka Diamond Information Institute Inc. for the quarterly period ended September 30, 2011, complieswith the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information containedin the quarterly report Form 10-Q fairly presents in all material respects the financial condition and results of operations ofTherapy Cells, Inc., fka Diamond Information Institute Inc.

 

Date: October 10, 2019

 

 

/s/ “Paul Knudson”

Paul Knudson

Chief Executive Officer

 

 

 

/s/ “Paul Knudson”

Paul Knudson

Chief Financial Officer, Principal Accounting Officer

 

A signed original of this written statement required by Section906, or other document authenticating, acknowledging, or otherwise adopting the signatures that appear in typed form within theelectronic version of this statement required by Section 906, has been provided to Therapy Cells, Inc., fka Diamond InformationInstitute Inc. and will be retained by Therapy Cells, Inc., fka Diamond Information Institute Inc. and furnished to the Securitiesand Exchange Commission or its staff upon request.
| 1. | Such      amended Quarterly Report on Form 10-Q for the period      ending March 31, 2009, fully complies with the requirements of      section 13(a) or 15(d) of the Securities Exchange Act of 1934;      and |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2. | The      information contained in such amended Quarterly Report on Form 10-Q for      the period ending March 31, 2009, fairly presents, in all      material respects, the financial condition and results of operations of      Formulawon, Inc. |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Date: October      2, 2009 |
|--------------------------------------|

| By:    | /s/ Fitra Iriani                                                                                                                               |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------|
|   | Fitra      Iriani                                                                                                                              |
|   | Chairman      of the Board of Directors,Chief      Executive Officer,Chief      Financial Officer,Controller,      Principal AccountingOfficer |
Exhibit 31.1  Section 302 Certification of Chief Executive Officer and Chief Financial Officer   I, Mordechai Guttman, certify that:  1. I have reviewed this quarterly report on Form 10-Q of HPC POS SYSTEM, CORP.  2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;  3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;  4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and have:  a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to me by others within those entities, particularly during the period in which this quarterly report is being prepared;  b) evaluated the effectiveness of the registrants disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the Evaluation Date); and  c) presented in this quarterly report my conclusions about the effectiveness of the disclosure controls and procedures based on my evaluation as of the Evaluation Date;  5. I have disclosed, based on my most recent evaluation, to the registrants auditors and the audit committee of registrants board of directors (or persons performing the equivalent functions):  a) all significant deficiencies in the design or operation of internal controls which could adversely affect the registrants ability to record, process, summarize and report financial data and have identified for the registrants auditors any material weaknesses in internal controls; and  b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal controls  6. I have indicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of my most recent evaluation, including any corrective actions with regard to significant deficiencies and material weaknesses.  Date: February 16, 2009  /s/ Mordechai Guttman Mordechai Guttman Title: President and Chief Financial Officer
# C_2011067EN.01001001.xml

| 2.3.2011 | EN | Official Journal of the European Union | C 67/10 |
| --- | --- | --- | --- |

2.3.2011

EN

Official Journal of the European Union

C 67/10

---

Interest rate applied by the European Central Bank to its main refinancing operations (1):

1

1,00 % on 1 March 2011

Euro exchange rates (2)

2

1 March 2011

2011/C 67/06

1 euro =

1 euro =

| | Currency | Exchange rate |
| --- | --- | --- |
| USD | US dollar | 1,3825 |
| JPY | Japanese yen | 113,39 |
| DKK | Danish krone | 7,4559 |
| GBP | Pound sterling | 0,84940 |
| SEK | Swedish krona | 8,7090 |
| CHF | Swiss franc | 1,2849 |
| ISK | Iceland króna | |
| NOK | Norwegian krone | 7,7120 |
| BGN | Bulgarian lev | 1,9558 |
| CZK | Czech koruna | 24,355 |
| HUF | Hungarian forint | 272,64 |
| LTL | Lithuanian litas | 3,4528 |
| LVL | Latvian lats | 0,7045 |
| PLN | Polish zloty | 3,9725 |
| RON | Romanian leu | 4,2120 |
| TRY | Turkish lira | 2,2214 |
| AUD | Australian dollar | 1,3572 |
| CAD | Canadian dollar | 1,3408 |
| HKD | Hong Kong dollar | 10,7668 |
| NZD | New Zealand dollar | 1,8397 |
| SGD | Singapore dollar | 1,7562 |
| KRW | South Korean won | 1 550,25 |
| ZAR | South African rand | 9,6111 |
| CNY | Chinese yuan renminbi | 9,0816 |
| HRK | Croatian kuna | 7,4222 |
| IDR | Indonesian rupiah | 12 163,51 |
| MYR | Malaysian ringgit | 4,1897 |
| PHP | Philippine peso | 60,026 |
| RUB | Russian rouble | 39,6750 |
| THB | Thai baht | 42,235 |
| BRL | Brazilian real | 2,2991 |
| MXN | Mexican peso | 16,7175 |
| INR | Indian rupee | 62,1430 |

Currency

Exchange rate

USD

US dollar

1,3825

JPY

Japanese yen

113,39

DKK

Danish krone

7,4559

GBP

Pound sterling

0,84940

SEK

Swedish krona

8,7090

CHF

Swiss franc

1,2849

ISK

Iceland króna

NOK

Norwegian krone

7,7120

BGN

Bulgarian lev

1,9558

CZK

Czech koruna

24,355

HUF

Hungarian forint

272,64

LTL

Lithuanian litas

3,4528

LVL

Latvian lats

0,7045

PLN

Polish zloty

3,9725

RON

Romanian leu

4,2120

TRY

Turkish lira

2,2214

AUD

Australian dollar

1,3572

CAD

Canadian dollar

1,3408

HKD

Hong Kong dollar

10,7668

NZD

New Zealand dollar

1,8397

SGD

Singapore dollar

1,7562

KRW

South Korean won

1 550,25

ZAR

South African rand

9,6111

CNY

Chinese yuan renminbi

9,0816

HRK

Croatian kuna

7,4222

IDR

Indonesian rupiah

12 163,51

MYR

Malaysian ringgit

4,1897

PHP

Philippine peso

60,026

RUB

Russian rouble

39,6750

THB

Thai baht

42,235

BRL

Brazilian real

2,2991

MXN

Mexican peso

16,7175

INR

Indian rupee

62,1430

---

(1)  Rate applied to the most recent operation carried out before the indicated day. In the case of a variable rate tender, the interest rate is the marginal rate.

1

(2)  Source: reference exchange rate published by the ECB.

2

Source:

---
NIOSH Conformity Assessment

Interpretation Notice

NIOSH CA 2019-1017

May 2019

 

NIOSH acceptance of breathing gas cylinders marked in accordance with 49 

C.F.R. Part 178 and ISO 11119-2
Document Number

NIOSH CA 2019-1017

Page 2 of 2

1 SUMMARY

Pursuant to 42 C.F.R. Part 84 (see § 84.81(a)), NIOSH requires that compressed breathing gas and 

liquefied breathing gas containers (cylinders) must meet minimum requirements of the Department 

of Transportation (DOT) for interstate shipment of such containers when fully charged. Cylinders 

conforming to International Organization for Standardization (ISO) 11119-2, Gas cylinders of 

composite construction – Specification and test methods – Part 2: Fully wrapped fiber reinforced 

composite gas cylinders with load-sharing liners and bearing a DOT competent authority approval are 

considered to be in compliance with DOT regulations for transportation to, from, and within the 

United States.

NIOSH considers cylinders originating in Canada (CAN) that are in compliance with DOT regulations 

to be in compliance with the requirements in 42 C.F.R. Part 84. 

2 AUTHORITY

Approval of Respiratory Protective Devices, 42 C.F.R. Part 84

3 REFERENCES

Approval of Respiratory Protective Devices, 42 C.F.R. Part 84

General Information, Regulations, and Definitions, 49 C.F.R. Part 171

Specifications for Packaging’s, 49 C.F.R. Part 178

Subject: NIOSH acceptance of breathing gas cylinders marked in accordance with 

49 C.F.R. Part 178 and ISO 11119-2
# Continuation of the National Emergency With Respect to the Risk of Nuclear Proliferation Created by the Accumulation of Weapons-Usable Fissile Material in the Territory of the Russian Federation

                        On June 21, 2000, President Clinton issued Executive Order 13159 (the “order”) blocking property and interests in property of the Government of the Russian Federation that are in the United States, that hereafter come within the United States, or that are or hereafter come within the possession or control of United States persons that are directly related to the implementation of the Agreement Between the Government of the United States of America and the Government of the Russian Federation Concerning the Disposition of Highly Enriched Uranium Extracted from Nuclear Weapons, dated February 18, 1993, and related contracts and agreements (collectively, the “HEU Agreements”). The HEU Agreements allow for the downblending of highly enriched uranium derived from nuclear weapons to low enriched uranium for peaceful commercial purposes. The order invoked the authority, inter alia, of the International Emergency Economic Powers Act (50 U.S.C. 1701*et seq*.) and declared a national emergency to deal with the unusual and extraordinary threat to the national security and foreign policy of the United States posed by the risk of nuclear proliferation created by the accumulation of a large volume of weapons-usable fissile material in the territory of the Russian Federation.                    

                        The national emergency declared on June 21, 2000, must continue beyond June 21, 2008, to provide continued protection from attachment, judgment, decree, lien, execution, garnishment, or other judicial process for the property and interests in property of the Government of the Russian Federation that are directly related to the implementation of the HEU Agreements and subject to U.S. jurisdiction. Therefore, in accordance with section 202 (d) of the National Emergencies Act (50 U.S.C. 1622(d)), I am continuing for 1 year the national emergency with respect to the risk of nuclear proliferation created by the accumulation of weapons-usable fissile material in the territory of the Russian Federation. This notice shall be published in the                         **Federal Register**                         and transmitted to the Congress.                    

[FR Doc. 08-1375

Billing code 3195-W8-P
**Exhibit 31.1**

**CERTIFICATION**

I, Clifford K.Bolen, the President of Vita Food Products, Inc., certify that:

1.      I have reviewed this annual report on Form10-K of Vita Food Products, Inc.;

2.      Based on my knowledge, this report doesnot contain any untrue statement of a material fact or omit to state a materialfact necessary to make the statements made, in light of the circumstances underwhich such statements were made, not misleading with respect to the periodcovered by this annual report;

3.      Based on my knowledge, the financialstatements, and other financial information included in this annual report,fairly present in all material respects the financial condition, results ofoperations and cash flows of the registrant as of, and for, the periods presentedin this annual report;

4.      The registrant’s other certifying officerand I am responsible for establishing and maintaining disclosure controls andprocedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for theregistrant and have:

a)      Designed such disclosure controls andprocedures, or caused such controls and procedures to be designed under oursupervision, to ensure that material information relating to the registrant,including its consolidated subsidiaries, is made known to us by others withinthose entities, particularly during the period in which this report is beingprepared;

b)     Evaluated the effectiveness of theregistrant’s disclosure controls and procedures and presented in this reportour conclusions about the effectiveness of the disclosure controls andprocedures, as of the end of the period covered by this report based on suchevaluation; and

c)      Disclosed in this annual report any changein the registrant’s internal control over financial reporting that occurredduring the registrant’s most recent fiscal year that has materially affected,or is reasonably likely to materially affect, the registrant’s internal controlover financial reporting; and

5.      The registrant’s other certifying officerand I have disclosed, based on our most recent evaluation of internal controlover financial reporting, to the registrant’s auditors and the audit committeeof the registrant’s board of directors (or persons performing the equivalentfunctions):

a)      All significant deficiencies and materialweaknesses in the design or operation of internal control over financialreporting which are reasonably likely to adversely affect the registrant’sability to record, process, summarize and report financial information; and

b)     Any fraud, whether or not material, that involves management orother employees who have a significant role in the registrant’s internalcontrol over financial reporting.

 

 

Date:  April17, 2007

 
| By:    |   | /s/ Clifford K. Bolen                       |   |
|--------|--------|---------------------------------------------|--------|
|   |   | Clifford K. Bolen                           |   |
|   |   | President and Chief Executive Officer       |   |
|   |   | (Principal Executive and Financial Officer) |   |

 

 

56

----
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Corporation for National and Community Service

The Board of Directors of the Corporation for National and Community Service gives notice of the following meeting: 

      ( print page 28437)    

# Date and Time:

 Tuesday, May 20, 2008, 4 p.m.-5:30 p.m. 

# Place

: Corporation for National and Community Service; 8th Floor; 1201 New York Avenue, NW., Washington, DC 20525. 

# Status:

 Open. 

# Matters To Be Considered: 

I. Chair's Opening Comments 

II. Consideration of Previous Meetings Minutes 

III. CEO Report 

IV. Committee Reports 
    - MAG Committee
    - Program Committee
    - Strategic Partnerships Committee

V. Impact of AmeriCorps Week and the Longitudinal Study 

Presentation by Millicent Williams, Executive Director, Serve DC and Sally Prouty, President and CEO of The Corps Network 

VI. Public Comments 

Accomodations: Anyone who needs an interpreter or other accommodation should notify the Corporation's contact person by 5 p.m. on Monday, May 19, 2008. 

# FOR MORE INFORMATION CONTACT: 

                        Lisa Guccione, Office of the CEO, Corporation for National and Community Service, 10th Floor, Room 10207, 1201 New York Avenue, NW., Washington, DC 20525. Phone (202) 606-6637. Fax (202) 606-3460. TDD: (202) 606-3472. E-mail:                         *lguccione@cns.gov*.                     

Dated: May 13, 2008. 

Frank R. Trinity, 

General Counsel. 

[FR Doc. 08-1269 Filed 5-13-08; 4:33 pm] 

BILLING CODE 6050-$$-P
AGENDA

Advisory Board on Radiation and Worker Health – Meeting 68

Teleconference Meeting

March 31, 2010; 11:00 a.m. Eastern Time

Teleconference Phone: 866-659-0537

Participant Code: 9933701

11:00 a.m. (Eastern Time) Start

• Roll-call – Mr. Katz, DFO

• Welcome – Dr. Melius, Chair

• Recording Vote on Westinghouse Electric Corp. SEC Petition – Mr. Katz, DFO

• Canoga Avenue Facility SEC Petition – Dr. Hughes, DCAS

– Revised class definition

– Possible vote

• University of Rochester Atomic Energy Project SEC Petition – Dr. Hughes, DCAS

– Update on data capture

• Chapman Valve & Blockson Chemical SEC Petitions – Dr. Neton, DCAS

– Isotopic analysis of enriched uranium samples at Chapman Valve 

– New members: further questions?

• Discussion of NIOSH 10-Year Program Review – Dr. Melius, Chair

• DCAS Facility Record Search Methods – Mr. Rutherford, DCAS

• SEC Class Definitions Analysis (update) – Mr. Rutherford, DCAS

• Special Exposure Cohort (SEC) Petition Status Update – Mr. Rutherford, DCAS

– Update on petitions to be presented at the May 2010 Board meeting

• Updates from Work Groups and Subcommittees (as necessary) – WG/SC Chairs

• New WG Assignments – Dr. Melius, Chair

• Managing Conflicts When Tasking SC&A – Mr. Katz, DFO

• Tasking SC&A – Dr. Melius, Chair

• Board Correspondence – Dr. Melius, Chair

• Future Plans/Suggestions for the May 2010 Board Meeting Agenda – All Board Members
**Exhibit 13.1**

 
| BASF Aktiengesellschaft |   |  |
|-------------------------|--------|--|

 

**CERTIFICATIONPURSUANT TO 18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TO SECTION 906 OF THESARBANES-OXLEY ACT**

 

In connectionwith the Annual Report on Form 20-F of BASF Aktiengesellschaft, a Germancorporation (“the Company”) for the year ended December 31, 2005 asfiled with the Securities and Exchange Commission on March 14, 2006 (the “Report”)the undersigned, Dr. Jürgen Hambrecht, Chairman of the Board of ExecutiveDirectors of BASF Aktiengesellschaft, hereby certifies, pursuant to18 U.S.C. Section 1350, that to his knowledge:

 

1.               The Report fully complies with therequirements of Section 13(a) or 15(d) of the SecuritiesExchange Act of 1934; and

 

2.               The information contained in the Reportfairly presents, in all material respects, the financial condition and resultsof operations of the Company.

 

 
| Dated: March 1, 2006 |   |                                          |   |
|---------------------------|--------|-----------------------------------------------|--------|
|                      |   |                                          |   |
|                      |   |                                               |
|                      | Name:  | Dr. Jürgen Hambrecht                |
|                      | Title: | Chairman of the Board of Executive  Directors |

 

----